NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market on Tuesday a 12 percent drop in total revenues for its fiscal fourth quarter.

For the three months ended July 31, the company took in $23.3 million in revenues, down from $26.4 million a year ago. Clinical laboratory services shrank to $14.0 million from $15.9 million, while product revenues retreated to $8.0 million from $8.9 million. Royalty and license fee income was down to $1.3 million from $1.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.